This was the stock's second consecutive day of gains.

The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson (NYSE: JNJ) higher in 2025. While each produced a solid quarter ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of $136.00. The company’s shares closed yesterday at ...

Abbott Laboratories (NYSE:ABT) reported its Q3 2024 earnings, meeting EPS expectations while slightly missing revenue forecasts. The company posted an EPS of $1.34, aligning with analysts' predictions ...

Good morning and thank you for standing by. Welcome to Abbott’s Fourth Quarter 2024 Earnings Conference Call. All participants will be able to listen only until the question-and-answer portion ...

Abbott Laboratories posted lower-than-expected sales in its latest quarter despite growth across most of its segments, though shares rose as the company forecast strong earnings growth for 2025.

(Reuters) - Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects new device launches and growing demand for its glucose monitors to offset a ...

In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other stocks expected to post impressive earnings this week. The earnings season is in full flow ...

At one point this season, the New Jersey Devils looked as if they might be the best team in the NHL. That has not been the case lately, as the Devils' offense flails and they slide further down ...

The S&P 500 briefly hit 6,100 points on Wednesday, reaching a fresh all-time high as Wall Street embraced a powerful mix of strong corporate earnings and President Donald Trump's bold $500 billion ...

Abbott Laboratories posted lower-than-expected sales in its latest quarter, dented in part by diminished demand for Covid-19 testing-related products. The healthcare-products manufacturer logged ...

Abbott Laboratories expects first quarter 2025 adjusted EPS of $1.05-$1.09 versus consensus of $1.11. Price Action: ABT stock is up 0.72% at $117.64 at the last check Wednesday.